These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20556834)

  • 21. Colchicine treatment effects on liver cirrhosis assessed by liver blood flow measurements.
    Tăpălagă D; Dumitraşcu D; Cotul S; Stanciu L; Tamaş S
    Med Interne; 1986; 24(1):69-73. PubMed ID: 3704505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum determination of N-terminal peptide of type III procollagen as a marker of fibrotic activity].
    García Montes JM; De Bonilla Blánez F; Herrerías Gutiérrez JM
    Rev Esp Enferm Apar Dig; 1989 Mar; 75(3):241-5. PubMed ID: 2734469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type III procollagen peptide and PZ-peptidase serum levels in pre-cirrhotic liver diseases.
    Morelli A; Vedovelli A; Fiorucci S; Angelini GP; Fini C; Palmerini CA; Floridi A
    Clin Chim Acta; 1985 May; 148(2):87-95. PubMed ID: 3888456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective randomized trial of colchicine in prevention of liver cirrhosis in chronic hepatitis B patients.
    Lin DY; Sheen IS; Chu CM; Liaw YF
    Aliment Pharmacol Ther; 1996 Dec; 10(6):961-6. PubMed ID: 8971295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity.
    Ramadori G; Zöhrens G; Manns M; Rieder H; Dienes HP; Hess G; Meyer KH; Büschenfelde Z
    Eur J Clin Invest; 1991 Jun; 21(3):323-30. PubMed ID: 1909636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Serum aminoterminal peptide of type III procollagen (PIIINP) and transforming growth factor-beta1 (TGF-beta1) levels in patients with chronic hepatitis B and C].
    Marek B; Kajdaniuk D; Janczewska-Kazek E; Beniowski M; Swietochowska E; Kos-Kudła B; Ostrowska Z; Mazurek U; Wilczok T; Nowak M; Siemińska L; Borgiel-Marek H; Strzyzewski A; Januła A; Sierek K; Niedzielski Z
    Pol Arch Med Wewn; 2003 Jun; 109(6):603-8. PubMed ID: 14567092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis.
    Weng HL; Cai WM; Liu RH
    World J Gastroenterol; 2001 Feb; 7(1):42-8. PubMed ID: 11819731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.
    Vuoristo M; Färkkilä M; Karvonen AL; Leino R; Lehtola J; Mäkinen J; Mattila J; Friman C; Seppälä K; Tuominen J
    Gastroenterology; 1995 May; 108(5):1470-8. PubMed ID: 7729640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Determination of serum procollagen-III peptide in chronic liver diseases. Clinical usefulness].
    Pagani A; Zigliani P; Pranzo A; Galante T
    Minerva Med; 1992 Nov; 83(11):715-20. PubMed ID: 1461542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis.
    Torres-Salinas M; Parés A; Caballería J; Jiménez W; Heredia D; Bruguera M; Rodés J
    Gastroenterology; 1986 May; 90(5 Pt 1):1241-6. PubMed ID: 3007261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating treatment options for chronic liver disease.
    Carey WD
    Cleve Clin J Med; 1989; 56(5):473-4. PubMed ID: 2504513
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease.
    Hayasaka A; Schuppan D; Ohnishi K; Okuda K; Hahn EG
    J Hepatol; 1990 Jan; 10(1):17-22. PubMed ID: 2307825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease.
    Weigand K; Zaugg PY; Frei A; Zimmermann A
    Hepatology; 1984; 4(5):835-8. PubMed ID: 6479852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study.
    Weng HL; Wang BE; Jia JD; Wu WF; Xian JZ; Mertens PR; Cai WM; Dooley S
    Clin Gastroenterol Hepatol; 2005 Aug; 3(8):819-28. PubMed ID: 16234012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serum markers and pathological evaluation in hepatitis fibrosis of chronic hepatitis B treated with interferon alpha].
    Deng L; Zhou Y; Peng X; Deng H; Deng Y; Yao J
    Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():66-7. PubMed ID: 11509145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis.
    Gabrielli GB; Capra F; Casaril M; Squarzoni S; Tognella P; Dagradi R; De Maria E; Colombari R; Corrocher R; De Sandre G
    Clin Chim Acta; 1997 Sep; 265(1):21-31. PubMed ID: 9352126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival.
    Morgan TR; Weiss DG; Nemchausky B; Schiff ER; Anand B; Simon F; Kidao J; Cecil B; Mendenhall CL; Nelson D; Lieber C; Pedrosa M; Jeffers L; Bloor J; Lumeng L; Marsano L; McClain C; Mishra G; Myers B; Leo M; Ponomarenko Y; Taylor D; Chedid A; French S; Kanel G; Murray N; Pinto P; Fong TL; Sather MR
    Gastroenterology; 2005 Apr; 128(4):882-90. PubMed ID: 15825072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis.
    Zhao W; Xue R; Zhou ZX; Kong WJ; Jiang JD
    Biomed Pharmacother; 2008 Dec; 62(10):730-1. PubMed ID: 18337056
    [No Abstract]   [Full Text] [Related]  

  • 40. Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers.
    Annoni G; Colombo M; Cantaluppi MC; Khlat B; Lampertico P; Rojkind M
    Hepatology; 1989 May; 9(5):693-7. PubMed ID: 2707736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.